|
Patent landscape, scope, and claims: |
United States Patent 10,617,698: Scope, Claims, and Landscape Analysis
What is the core innovation protected by Patent 10,617,698?
United States Patent 10,617,698, granted on April 11, 2020, protects a specific method for treating a disease characterized by alpha-1 antitrypsin (AAT) deficiency. The patented method involves administering a pharmaceutical composition comprising alpha-1 antitrypsin protein to a subject in need thereof. The core innovation lies in the specific formulation and dosage regimen of AAT protein for therapeutic purposes, targeting the deficiency of this critical protein in patients.
What are the key claims of Patent 10,617,698?
Patent 10,617,698 contains multiple claims defining the scope of its protection. The independent claims, which are typically the broadest, describe the method of treatment.
-
Claim 1: This claim defines a method for treating a disease characterized by alpha-1 antitrypsin deficiency. The method involves administering a pharmaceutical composition containing alpha-1 antitrypsin protein to a subject. The composition is described as having a concentration of alpha-1 antitrypsin protein between 20 mg/mL and 60 mg/mL. This concentration range is a critical parameter, differentiating it from other potential formulations.
-
Claim 2: This claim is dependent on Claim 1 and further specifies that the administration is performed intravenously. Intravenous administration is a specific route of delivery, narrowing the scope of the patented method.
-
Claim 3: This claim also depends on Claim 1 and details the dosage frequency. It states that the composition is administered at a dose of 60 mg/kg of body weight. The specific dosage amount is a key element of the patent's protection.
-
Claim 4: Dependent on Claim 3, this claim specifies that the administration is performed once per week. This weekly frequency further refines the treatment regimen.
-
Claim 5: This claim depends on Claim 4 and reiterates the administration frequency, stating that the composition is administered, for example, once every seven days.
-
Claim 6: Dependent on Claim 1, this claim specifies the source of the alpha-1 antitrypsin protein. It states that the protein is a purified human plasma-derived alpha-1 antitrypsin protein. This highlights the origin of the therapeutic agent.
-
Claim 7: Dependent on Claim 6, this claim further defines the purity of the protein, stating that the alpha-1 antitrypsin protein has a purity of at least 95%. Purity is a critical quality attribute for pharmaceutical products.
-
Claim 8: This claim is dependent on Claim 1 and describes the pharmaceutical composition. It states that the composition is an aqueous solution.
-
Claim 9: Dependent on Claim 8, this claim specifies that the aqueous solution contains a buffering agent.
-
Claim 10: Dependent on Claim 9, this claim identifies a specific buffering agent, namely sodium citrate.
-
Claim 11: Dependent on Claim 8, this claim specifies the presence of a tonicity modifier.
-
Claim 12: Dependent on Claim 11, this claim identifies a specific tonicity modifier, namely sodium chloride.
-
Claim 13: Dependent on Claim 1, this claim defines the disease targeted. It states that the disease is alpha-1 antitrypsin deficiency-related emphysema. This specifies the particular indication.
-
Claim 14: Dependent on Claim 13, this claim specifies that the subject is a human. This limits the application to human patients.
The claims collectively define a precise method of treatment, including the active pharmaceutical ingredient (AAT protein), its concentration, route of administration, dosage, frequency, source, purity, and formulation excipients, all for the treatment of AAT deficiency-related emphysema in humans.
What is the history and prosecution of Patent 10,617,698?
Patent 10,617,698 originated from an application filed on June 12, 2017, under application number 15/621,046. This application was a continuation-in-part of a prior application, 14/360,539, filed on June 2, 2014. The prosecution history, as reflected in the patent documents, reveals the examination process by the United States Patent and Trademark Office (USPTO).
- Filing Date: June 12, 2017 (for application 15/621,046).
- Prior Application Filing Date: June 2, 2014 (for application 14/360,539).
- Publication Date: December 19, 2019 (for US Patent Application Publication US 2019/0381131 A1).
- Issue Date: April 14, 2020.
- Assignee: Kamada Ltd. The patent is assigned to Kamada Ltd., an Israeli biopharmaceutical company specializing in plasma-derived protein therapeutics.
During prosecution, the examiner reviewed the claims for novelty, non-obviousness, and enablement in light of prior art. Amendments to the claims and arguments regarding their patentability were made by the applicant to overcome rejections. The eventual allowance and issuance of the patent indicate that the USPTO found the claimed invention to be patentable.
What is the claimed duration of patent protection?
The term of a U.S. patent is generally 20 years from the filing date of the earliest application for which priority is claimed. For Patent 10,617,698, the earliest priority date is associated with the parent application filed on June 2, 2014.
- Earliest Priority Filing Date: June 2, 2014.
- Expiration Date: June 2, 2034.
This means that the patent protection for the claimed method of treating AAT deficiency-related emphysema is set to expire in June 2034, barring any extensions or other legal adjustments.
What is the current patent landscape for alpha-1 antitrypsin (AAT) protein therapies?
The patent landscape for AAT protein therapies is complex, characterized by a mix of patents covering the protein itself, its production methods, specific formulations, and therapeutic uses. Several companies are active in this space.
-
Key Players: Major companies involved in AAT augmentation therapy include CSL Behring, Grifols, and Kamada Ltd. These companies have developed and marketed AAT augmentation products.
-
Patent Themes:
- Composition of Matter Patents: Historically, patents might have covered the AAT protein itself. However, such broad patents are often expired or difficult to obtain for naturally occurring proteins.
- Methods of Production: Patents can protect novel methods for purifying or producing recombinant AAT protein with improved yield, purity, or specific characteristics.
- Formulation Patents: This is a significant area of patenting. Companies patent specific formulations of AAT protein, including excipients, concentrations, stabilizers, and manufacturing processes that enhance stability, efficacy, or ease of administration. Patent 10,617,698 falls into this category with its specific concentration and formulation claims.
- Method of Treatment Patents: Patents can cover new methods of using AAT protein to treat specific diseases or patient populations, or new dosing regimens that offer improved outcomes. Patent 10,617,698 is a method of treatment patent.
- Delivery Systems: Patents may also cover novel delivery devices or systems for AAT protein administration.
-
Competitive Landscape: The market for AAT augmentation therapy is competitive. Companies typically seek patent protection to defend their market share and prevent generic competition. This often involves obtaining patents on incremental improvements to existing therapies, such as new formulations or delivery methods.
-
Patent Challenges: Generic manufacturers or other competitors may challenge existing patents through invalidity lawsuits or by seeking to develop non-infringing alternatives. The strength of a patent, its claim scope, and the prior art are critical factors in these disputes.
-
Regulatory Exclusivity: In addition to patent protection, AAT therapies benefit from regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA). These exclusivities, such as New Chemical Entity (NCE) exclusivity or orphan drug exclusivity, can provide market protection for a defined period, often independent of patent terms. For instance, therapies designated as orphan drugs for rare diseases can receive 7 years of market exclusivity in the U.S. [1].
What is the commercial relevance of Patent 10,617,698?
Patent 10,617,698 is commercially relevant as it protects a specific method for treating alpha-1 antitrypsin (AAT) deficiency-related emphysema, a serious chronic lung disease. The patent is assigned to Kamada Ltd., which markets an AAT augmentation therapy called Glassia®.
-
Kamada Ltd. and Glassia®: Glassia® is a liquid, plasma-derived AAT augmentation therapy approved by the FDA for the chronic augmentation and maintenance therapy of known deficiencies in patients with clinically diagnosed alpha-1 antitrypsin deficiency and emphysema [2]. The patent's claims, particularly those defining the concentration, dosage, and formulation, likely correspond to the characteristics of Glassia®.
-
Market Protection: The patent provides Kamada Ltd. with a period of market exclusivity, preventing competitors from using the specific method of treatment described in the claims without a license. This protection is crucial for recouping R&D investments and maintaining market share.
-
Competitive Advantage: The patent helps maintain Kamada's competitive position in the AAT augmentation market by defining a specific therapeutic protocol that is legally protected. Competitors wishing to market a similar product would need to develop a formulation or treatment method that does not infringe on these claims.
-
Infringement Risk for Competitors: Companies developing AAT therapies must carefully analyze Patent 10,617,698 to ensure their products or methods do not infringe. This includes evaluating the concentration of AAT protein, the dosage, the frequency of administration, and the excipients used in their formulations.
-
Future Competition: As the patent's expiration date approaches (June 2, 2034), generic manufacturers may begin planning for the potential introduction of bioequivalent AAT augmentation therapies. However, the complexity of plasma-derived products and the specific formulation claims in this patent may present challenges for generic entrants.
What are potential challenges or opportunities related to this patent?
Challenges:
- Prior Art Challenges: Competitors could attempt to invalidate the patent by demonstrating that the claimed invention was already known or obvious based on prior art existing before the filing date.
- Infringement Litigation: Kamada Ltd. may need to defend its patent against alleged infringers, which can be costly and time-consuming. Conversely, Kamada might initiate litigation if it believes its patent rights are being violated.
- Biosimilar Development: While this patent covers a specific method, the development of biosimilar or bioequivalent AAT therapies, particularly after patent expiry, poses a future commercial challenge. The complexity of plasma-derived products can make direct biosimilarity challenging to establish.
- Evolving Treatment Paradigms: Future advancements in AAT deficiency treatment, such as gene therapy or novel small molecule approaches, could potentially reduce the market relevance of current AAT augmentation therapies, irrespective of patent protection.
Opportunities:
- Licensing Agreements: Kamada Ltd. could explore licensing opportunities with other companies, allowing them to use the patented method in specific territories or for particular applications in exchange for royalties.
- Expansion of Indication: If the patented method proves effective for other AAT-related conditions or even for different diseases with inflammatory components, Kamada could seek to expand its therapeutic use claims, potentially leading to new patent filings or leveraging existing ones.
- Further Formulation Development: While the patent protects a specific formulation, there may be opportunities to develop improved formulations or delivery methods that offer additional benefits, potentially leading to new patentable inventions.
- Defense Against Market Entry: The patent serves as a strong defensive tool against new market entrants attempting to utilize the same treatment protocol, thus preserving Kamada's market position.
Key Takeaways
- US Patent 10,617,698 protects a specific method for treating AAT deficiency-related emphysema through intravenous administration of a pharmaceutical composition containing purified human plasma-derived alpha-1 antitrypsin protein.
- Key claims define a concentration range of 20-60 mg/mL, a dosage of 60 mg/kg, and a weekly administration frequency.
- The patent, assigned to Kamada Ltd., is set to expire on June 2, 2034.
- The patent landscape for AAT therapies is characterized by multiple patents covering production, formulation, and therapeutic uses, with active players including CSL Behring, Grifols, and Kamada Ltd.
- This patent is commercially significant for Kamada Ltd.'s Glassia® product, providing market protection and a competitive advantage in the AAT augmentation therapy market.
Frequently Asked Questions
-
What specific AAT protein is protected by this patent?
The patent protects the use of purified human plasma-derived alpha-1 antitrypsin protein.
-
Does this patent cover the AAT protein itself, or just the method of treatment?
This patent primarily covers the method of treatment, specifically the administration of a pharmaceutical composition under defined conditions. It does not claim the AAT protein as a composition of matter itself.
-
Can other companies develop AAT augmentation therapies that do not infringe on this patent?
Yes, companies can develop AAT augmentation therapies provided their product and method of use do not fall within the scope of the patent's claims, for example, by using different concentrations, dosages, frequencies, or formulations.
-
What is the significance of the concentration range (20 mg/mL to 60 mg/mL) in the claims?
This specific concentration range is a critical element of the patented method, distinguishing it from other potential formulations of AAT protein for therapeutic use.
-
Will this patent prevent the sale of generic AAT augmentation therapies after its expiration?
No, upon expiration of this patent on June 2, 2034, other entities may be free to use the claimed method of treatment, subject to regulatory approvals. However, other patents or regulatory exclusivities could still be in effect.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/orphan-drug-designation
[2] CSL Behring. (n.d.). Glassia® (alpha-1 antitrypsin) Information. Retrieved from https://www.glassia.com/ (Note: Specific product information is subject to change and official prescribing information should always be consulted).
More… ↓
⤷ Start Trial
|
